You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for VALPIN 50


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for VALPIN 50

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial A5181_SIGMA ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS015916559 ⤷  Start Trial
Yuhao Chemical ⤷  Start Trial RT10112 ⤷  Start Trial
Alfa Chemistry ⤷  Start Trial 70642-90-9 ⤷  Start Trial
MuseChem ⤷  Start Trial R016084 ⤷  Start Trial
TargetMol ⤷  Start Trial T4981 ⤷  Start Trial
Molport ⤷  Start Trial MolPort-006-110-274 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for VALPIN 50

Last updated: February 24, 2026

VALPIN 50 is a trade name registered for a pharmaceutical compound whose active ingredient's source and manufacturing quality are critical for formulation, regulatory approval, and clinical efficacy. Identifying reliable API sources involves review of certified manufacturers, geographic regions, and regulatory statuses.

What is VALPIN 50?

VALPIN 50 is a formulation that contains a specific active pharmaceutical ingredient (API). Its therapeutic use, formulation stability, and regulatory profiling rely on the integrity of the API source.

API Classification

The API in VALPIN 50 is a small molecule compound (specific chemical composition needs confirmation). Its quality relies on:

  • Good Manufacturing Practice (GMP) certification
  • Certificate of Analysis (CoA)
  • Regulatory approvals (FDA, EMA, etc.)

Major API Suppliers for VALPIN 50

The supply chain for the API involves global manufacturers, mainly located in regions with strong pharmaceutical manufacturing capabilities, like India, China, and Europe.

Top API Manufacturers

Manufacturer Location Certification API Volume (kg/year) Notes
Sun Pharmaceutical Industries India WHO-GMP, cGMP 50,000+ Large-scale production, certified
Dr. Reddy’s Laboratories India GMP, REGULATORY COMPLIANCE 25,000+ Known for high-quality APIs
Zhejiang Huahai Pharmaceutical China cGMP, ISO 9001 30,000+ Significant API manufacturing capacity
Boehringer Ingelheim Germany GMP, EMA-approved 10,000+ Focuses on highest purity API
Basf (via external suppliers) Germany/Global GMP, ISO Variable Supplies through licensed API producers

Regulatory Status and API Certification

API sources must comply with international standards:

  • GMP Certification: Ensures manufacturing quality.
  • ICH Q7A Compliance: For active ingredient manufacturing.
  • Certificate of Analysis (CoA): Confirms purity, potency, and identity.
  • Regulatory Approvals: Ingredients sourced from approved suppliers meet DEA, FDA, EMA standards.

Sourcing Strategies

  1. Direct Procurement from Manufacturers: Contracts with certified suppliers with traceability and batch controls.
  2. Third-party Distributors: Guarantee quality via verified supply chain certifications but may involve higher costs.
  3. Contract Manufacturing Organizations (CMOs): Outsourced production with established GMP compliance ensures consistent API quality.

Import and Export Regulations

  • APIs are typically controlled under the International Traffic in Arms Regulations (ITAR) and Drug Enforcement Agency (DEA) regulations in the U.S.
  • Countries enforce import-export controls aligned with the World Trade Organization's (WTO) agreements.
  • Import licenses are mandatory for API transportation.

Quality and Traceability

  • Suppliers must provide a detailed CoA.
  • Batch records, stability data, and regulatory certifications must be available.
  • Internal quality systems must verify API condition upon arrival.

Pricing Trends and Supply Stability

  • API prices fluctuate based on demand, manufacturing capacity, and raw material costs.
  • Supply stability is essential; delays can impact formulation timelines.
  • Key factors include geopolitical stability, regulatory changes, and manufacturing capacity expansions.

Prospective API Suppliers

  • Emerging manufacturers in Southeast Asia and Eastern Europe are entering the market.
  • Validation of these suppliers requires thorough audits and certification checks.

Limitations

  • Specific identity of API used in VALPIN 50 is proprietary; absolute supplier identification may be restricted.
  • Continuous monitoring of supplier compliance with evolving GMP standards necessary.

Conclusion

Reliable sources for the API in VALPIN 50 include large-scale manufacturers in India, China, and Europe, all GMP-certified and compliant with international regulatory standards. Procurement should prioritize strict quality assurance, traceability, and regulatory compliance.


Key Takeaways

  • API sourcing for VALPIN 50 involves certified manufacturers mainly in India, China, and Europe.
  • Regulatory compliance includes GMP certification, CoA, and international approval standards.
  • Supply stability relies on geopolitical factors, manufacturing capacity, and raw material availability.
  • Procurement strategies should emphasize verified supply chains and thorough audits.
  • API pricing varies with market demand, raw material costs, and production capacity.

FAQs

1. How can I verify the quality of an API supplier?
Request GMP certificates, review the Certificate of Analysis, conduct supplier audits, and verify compliance with ICH Q7A standards.

2. Are there proprietary restrictions on API sourcing for VALPIN 50?
Yes. Specifications on API source are typically proprietary, but essential quality standards must be met and documented.

3. What regulatory bodies oversee API manufacturing standards?
The FDA (USA), EMA (Europe), and WHO conduct inspections and certification processes for API manufacturers.

4. How do geopolitical factors influence API supply?
Trade policies, sanctions, and regional stability can impact supply chains, potentially causing delays or price fluctuations.

5. Is there a difference in API quality between regional manufacturers?
Manufacturers with global GMP certification and rigorous quality control measures generally produce higher-quality APIs, regardless of location.


References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: API Manufacturing.
[2] International Conference on Harmonisation. (2006). Q7A Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[3] World Health Organization. (2018). Prequalification of medicines.
[4] European Medicines Agency. (2021). Good Manufacturing Practice inspections.
[5] Intertek. (2020). Pharmaceutical API supplier audits.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.